We have advised SENISCA, a University of Exeter spin-out, on a multi-year joint research, development and commercialisation licence agreement with L'Oréal.
SENISCA is a biotech company that develops technology focused on reversing the process of cellular aging (senescence) via the development of RNA senotherapeutics that specifically target the molecular causes of the process of aging.
The multi-year partnership will see SENISCA's expertise and proprietary technology be further developed for cosmetic applications.
Our team consisted of Colin McCall and Charlie Adams from the Patents team.
